Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series.

Conclusions: In obese Japanese drug-naive patients who had type 2 diabetes, treatment with liraglutide (0.9 mg once daily for 24 weeks) reduced body fat, especially visceral fat and intrahepatic fat, while having no significant effect on skeletal muscle. PMID: 30834046 [PubMed]

https://www.ncbi.nlm.nih.gov/pubmed/30834046?dopt=Abstract

Source: Clin Med Res - February 28, 2019 Category: Research Authors: Ishii S, Nagai Y, Sada Y, Fukuda H, Nakamura Y, Matsuba R, Nakagawa T, Kato H, Tanaka Y Tags: J Clin Med Res Source Type: research